1.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
		                        		
		                        			
		                        			 Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment. 
		                        		
		                        		
		                        		
		                        	
2.Prospective Multicenter Observational Study on Postoperative Quality of Life According to Type of Gastrectomy for Gastric Cancer
Sung Eun OH ; Yun-Suhk SUH ; Ji Yeong AN ; Keun Won RYU ; In CHO ; Sung Geun KIM ; Ji-Ho PARK ; Hoon HUR ; Hyung-Ho KIM ; Sang-Hoon AHN ; Sun-Hwi HWANG ; Hong Man YOON ; Ki Bum PARK ; Hyoung-Il KIM ; In Gyu KWON ; Han-Kwang YANG ; Byoung-Jo SUH ; Sang-Ho JEONG ; Tae-Han KIM ; Oh Kyoung KWON ; Hye Seong AHN ; Ji Yeon PARK ; Ki Young YOON ; Myoung Won SON ; Seong-Ho KONG ; Young-Gil SON ; Geum Jong SONG ; Jong Hyuk YUN ; Jung-Min BAE ; Do Joong PARK ; Sol LEE ; Jun-Young YANG ; Kyung Won SEO ; You-Jin JANG ; So Hyun KANG ; Bang Wool EOM ; Joongyub LEE ; Hyuk-Joon LEE ;
Journal of Gastric Cancer 2025;25(2):382-399
		                        		
		                        			 Purpose:
		                        			This study evaluated the postoperative quality of life (QoL) after various types of gastrectomy for gastric cancer. 
		                        		
		                        			Materials and Methods:
		                        			A multicenter prospective observational study was conducted in Korea using the Korean Quality of Life in Stomach Cancer Patients Study (KOQUSS)-40, a new QoL assessment tool focusing on postgastrectomy syndrome. Overall, 496 patients with gastric cancer were enrolled, and QoL was assessed at 5 time points: preoperatively and at 1, 3, 6, and 12 months after surgery. 
		                        		
		                        			Results:
		                        			Distal gastrectomy (DG) and pylorus-preserving gastrectomy (PPG) showed significantly better outcomes than total gastrectomy (TG) and proximal gastrectomy (PG) with regard to total score, indigestion, and dysphagia. DG, PPG, and TG also showed significantly better outcomes than PG in terms of dumping syndrome and worry about cancer. Postoperative QoL did not differ significantly according to anastomosis type in DG, except for Billroth I anastomosis, which achieved better bowel habit change scores than the others. No domains differed significantly when comparing double tract reconstruction and esophagogastrostomy after PG. The total QoL score correlated significantly with postoperative body weight loss (more than 10%) and extent of resection (P<0.05 for both).Reflux as assessed by KOQUSS-40 did not correlate significantly with reflux observed on gastroscopy 1 year postoperatively (P=0.064). 
		                        		
		                        			Conclusions
		                        			Our prospective observation using KOQUSS-40 revealed that DG and PPG lead to better QoL than TG and PG. Further study is needed to compare postoperative QoL according to anastomosis type in DG and PG. 
		                        		
		                        		
		                        		
		                        	
3.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
		                        		
		                        			
		                        			 Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment. 
		                        		
		                        		
		                        		
		                        	
4.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
		                        		
		                        			
		                        			 Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment. 
		                        		
		                        		
		                        		
		                        	
5.Prospective Multicenter Observational Study on Postoperative Quality of Life According to Type of Gastrectomy for Gastric Cancer
Sung Eun OH ; Yun-Suhk SUH ; Ji Yeong AN ; Keun Won RYU ; In CHO ; Sung Geun KIM ; Ji-Ho PARK ; Hoon HUR ; Hyung-Ho KIM ; Sang-Hoon AHN ; Sun-Hwi HWANG ; Hong Man YOON ; Ki Bum PARK ; Hyoung-Il KIM ; In Gyu KWON ; Han-Kwang YANG ; Byoung-Jo SUH ; Sang-Ho JEONG ; Tae-Han KIM ; Oh Kyoung KWON ; Hye Seong AHN ; Ji Yeon PARK ; Ki Young YOON ; Myoung Won SON ; Seong-Ho KONG ; Young-Gil SON ; Geum Jong SONG ; Jong Hyuk YUN ; Jung-Min BAE ; Do Joong PARK ; Sol LEE ; Jun-Young YANG ; Kyung Won SEO ; You-Jin JANG ; So Hyun KANG ; Bang Wool EOM ; Joongyub LEE ; Hyuk-Joon LEE ;
Journal of Gastric Cancer 2025;25(2):382-399
		                        		
		                        			 Purpose:
		                        			This study evaluated the postoperative quality of life (QoL) after various types of gastrectomy for gastric cancer. 
		                        		
		                        			Materials and Methods:
		                        			A multicenter prospective observational study was conducted in Korea using the Korean Quality of Life in Stomach Cancer Patients Study (KOQUSS)-40, a new QoL assessment tool focusing on postgastrectomy syndrome. Overall, 496 patients with gastric cancer were enrolled, and QoL was assessed at 5 time points: preoperatively and at 1, 3, 6, and 12 months after surgery. 
		                        		
		                        			Results:
		                        			Distal gastrectomy (DG) and pylorus-preserving gastrectomy (PPG) showed significantly better outcomes than total gastrectomy (TG) and proximal gastrectomy (PG) with regard to total score, indigestion, and dysphagia. DG, PPG, and TG also showed significantly better outcomes than PG in terms of dumping syndrome and worry about cancer. Postoperative QoL did not differ significantly according to anastomosis type in DG, except for Billroth I anastomosis, which achieved better bowel habit change scores than the others. No domains differed significantly when comparing double tract reconstruction and esophagogastrostomy after PG. The total QoL score correlated significantly with postoperative body weight loss (more than 10%) and extent of resection (P<0.05 for both).Reflux as assessed by KOQUSS-40 did not correlate significantly with reflux observed on gastroscopy 1 year postoperatively (P=0.064). 
		                        		
		                        			Conclusions
		                        			Our prospective observation using KOQUSS-40 revealed that DG and PPG lead to better QoL than TG and PG. Further study is needed to compare postoperative QoL according to anastomosis type in DG and PG. 
		                        		
		                        		
		                        		
		                        	
6.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
		                        		
		                        			
		                        			 Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment. 
		                        		
		                        		
		                        		
		                        	
7.The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
Hwan Soo KIM ; Eun LEE ; Kyunghoon KIM ; Taek Ki MIN ; Dong In SUH ; Yoon Ha HWANG ; Sungsu JUNG ; Minyoung JUNG ; Young A PARK ; Minji KIM ; In Suk SOL ; You Hoon JEON ; Sung-Il WOO ; Yong Ju LEE ; Jong Deok KIM ; Hyeon-Jong YANG ; Gwang Cheon JANG ;
Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
		                        		
		                        			
		                        			 Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment. 
		                        		
		                        		
		                        		
		                        	
8.Prospective Multicenter Observational Study on Postoperative Quality of Life According to Type of Gastrectomy for Gastric Cancer
Sung Eun OH ; Yun-Suhk SUH ; Ji Yeong AN ; Keun Won RYU ; In CHO ; Sung Geun KIM ; Ji-Ho PARK ; Hoon HUR ; Hyung-Ho KIM ; Sang-Hoon AHN ; Sun-Hwi HWANG ; Hong Man YOON ; Ki Bum PARK ; Hyoung-Il KIM ; In Gyu KWON ; Han-Kwang YANG ; Byoung-Jo SUH ; Sang-Ho JEONG ; Tae-Han KIM ; Oh Kyoung KWON ; Hye Seong AHN ; Ji Yeon PARK ; Ki Young YOON ; Myoung Won SON ; Seong-Ho KONG ; Young-Gil SON ; Geum Jong SONG ; Jong Hyuk YUN ; Jung-Min BAE ; Do Joong PARK ; Sol LEE ; Jun-Young YANG ; Kyung Won SEO ; You-Jin JANG ; So Hyun KANG ; Bang Wool EOM ; Joongyub LEE ; Hyuk-Joon LEE ;
Journal of Gastric Cancer 2025;25(2):382-399
		                        		
		                        			 Purpose:
		                        			This study evaluated the postoperative quality of life (QoL) after various types of gastrectomy for gastric cancer. 
		                        		
		                        			Materials and Methods:
		                        			A multicenter prospective observational study was conducted in Korea using the Korean Quality of Life in Stomach Cancer Patients Study (KOQUSS)-40, a new QoL assessment tool focusing on postgastrectomy syndrome. Overall, 496 patients with gastric cancer were enrolled, and QoL was assessed at 5 time points: preoperatively and at 1, 3, 6, and 12 months after surgery. 
		                        		
		                        			Results:
		                        			Distal gastrectomy (DG) and pylorus-preserving gastrectomy (PPG) showed significantly better outcomes than total gastrectomy (TG) and proximal gastrectomy (PG) with regard to total score, indigestion, and dysphagia. DG, PPG, and TG also showed significantly better outcomes than PG in terms of dumping syndrome and worry about cancer. Postoperative QoL did not differ significantly according to anastomosis type in DG, except for Billroth I anastomosis, which achieved better bowel habit change scores than the others. No domains differed significantly when comparing double tract reconstruction and esophagogastrostomy after PG. The total QoL score correlated significantly with postoperative body weight loss (more than 10%) and extent of resection (P<0.05 for both).Reflux as assessed by KOQUSS-40 did not correlate significantly with reflux observed on gastroscopy 1 year postoperatively (P=0.064). 
		                        		
		                        			Conclusions
		                        			Our prospective observation using KOQUSS-40 revealed that DG and PPG lead to better QoL than TG and PG. Further study is needed to compare postoperative QoL according to anastomosis type in DG and PG. 
		                        		
		                        		
		                        		
		                        	
9.Evidence-based management guidelines for noncystic fibrosis bronchiectasis in children and adolescents
Eun LEE ; Kyunghoon KIM ; You Hoon JEON ; In Suk SOL ; Jong Deok KIM ; Taek Ki MIN ; Yoon Ha HWANG ; Hyun-Ju CHO ; Dong In SUH ; Hwan Soo KIM ; Yoon Hee KIM ; Sung-Il WOO ; Yong Ju LEE ; Sungsu JUNG ; Hyeon-Jong YANG ; Gwang Cheon JANG
Clinical and Experimental Pediatrics 2024;67(9):418-426
		                        		
		                        			
		                        			 Noncystic fibrosis bronchiectasis is a chronic respiratory disease that carries high socioeconomic and medical burdens and is caused by diverse respiratory illnesses. To improve clinical outcomes, early recognition, active treatment of exacerbations, and prevention of further exacerbations are essential. However, evidence for the treatment and prevention of acute exacerbation of noncystic fibrosis bronchiectasis, especially in children, is lacking. Therefore, the evidence- and consensus-based guidelines for medical and nonmedical treatment strategies for noncystic fibrosis bronchiectasis in children and adolescents were developed by the Korean Academy of Pediatric Allergy and Respiratory Disease using the methods recommended by the Grading of Recommendations Assessment, Development, and Evaluation working group with evidence published through July 2, 2020. This guideline encompasses evidence-based treatment recommendations as well as expert opinions, addressing crucial aspects of the treatment and management of non-cystic fibrosis bronchiectasis in children. This includes considerations for antibiotics and airway clearance strategies, particularly in areas where evidence may be limited. Large, well-designed, and controlled studies are required to accumulate further evidence of management strategies for noncystic fibrosis bronchiectasis in children and adolescents. 
		                        		
		                        		
		                        		
		                        	
10.Evidence-based management guidelines for noncystic fibrosis bronchiectasis in children and adolescents
Eun LEE ; Kyunghoon KIM ; You Hoon JEON ; In Suk SOL ; Jong Deok KIM ; Taek Ki MIN ; Yoon Ha HWANG ; Hyun-Ju CHO ; Dong In SUH ; Hwan Soo KIM ; Yoon Hee KIM ; Sung-Il WOO ; Yong Ju LEE ; Sungsu JUNG ; Hyeon-Jong YANG ; Gwang Cheon JANG
Clinical and Experimental Pediatrics 2024;67(9):418-426
		                        		
		                        			
		                        			 Noncystic fibrosis bronchiectasis is a chronic respiratory disease that carries high socioeconomic and medical burdens and is caused by diverse respiratory illnesses. To improve clinical outcomes, early recognition, active treatment of exacerbations, and prevention of further exacerbations are essential. However, evidence for the treatment and prevention of acute exacerbation of noncystic fibrosis bronchiectasis, especially in children, is lacking. Therefore, the evidence- and consensus-based guidelines for medical and nonmedical treatment strategies for noncystic fibrosis bronchiectasis in children and adolescents were developed by the Korean Academy of Pediatric Allergy and Respiratory Disease using the methods recommended by the Grading of Recommendations Assessment, Development, and Evaluation working group with evidence published through July 2, 2020. This guideline encompasses evidence-based treatment recommendations as well as expert opinions, addressing crucial aspects of the treatment and management of non-cystic fibrosis bronchiectasis in children. This includes considerations for antibiotics and airway clearance strategies, particularly in areas where evidence may be limited. Large, well-designed, and controlled studies are required to accumulate further evidence of management strategies for noncystic fibrosis bronchiectasis in children and adolescents. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail